ID   WM1862
AC   CVCL_C268
SY   WM-1862; WM 1862; EST75
DR   cancercelllines; CVCL_C268
DR   Cosmic; 972270
DR   Cosmic; 1047654
DR   Cosmic; 2163803
DR   ESTDAB; ESTDAB-075
DR   GEO; GSM156010
DR   IARC_TP53; 26081
DR   Progenetix; CVCL_C268
DR   Rockland; WM1862-01-0001
DR   Wikidata; Q54994200
RX   PubMed=15592718;
RX   PubMed=17260012;
RX   PubMed=23851445;
WW   https://www.wistar.org/our-scientists/meenhard-herlyn
CC   Part of: Wistar Institute melanoma cell line collection.
CC   Characteristics: Pigmented.
CC   HLA typing: A*32:01,68:01:02; B*14:01; C*08:01; DPB1*04:02,02:01:02; DQB1*02:01; DRB1*07:01 (PubMed=15592718).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012; Wistar).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=17260012; PubMed=23851445; Wistar).
CC   Omics: Array-based CGH.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
ST   Source(s): ESTDAB=ESTDAB-075; Wistar
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 9,11
ST   D16S539: 13
ST   D18S51: 12,17
ST   D19S433: 13,14
ST   D21S11: 28,29
ST   D2S1338: 24,25
ST   D3S1358: 16,18
ST   D5S818: 11,14
ST   D7S820: 10
ST   D8S1179: 13,14
ST   FGA: 20,21
ST   TH01: 7,9.3
ST   TPOX: 8,11
ST   vWA: 15,17
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 02-05-24; Version: 25
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A.,
RA   Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=17260012; DOI=10.1038/sj.onc.1210252;
RA   Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M.,
RA   Guldberg P., Borg A.;
RT   "Genomic profiling of malignant melanoma using tiling-resolution
RT   arrayCGH.";
RL   Oncogene 26:4738-4748(2007).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//